Pharmaceutical industry veteran Dan Barton to serve as Chief Executive Officer. Exton PA, September 21, 2023 — Spherix Global Insights,
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents
Will Pfizer’s marketing power help Zavzpret™ rapidly gain share in the crowded migraine market? Exton, PA., August 17, 2023 –In February
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE
US neurologists in Spherix’s in-house physician network complete a patient chart audit of over 600 patients with gMG. Exton, PA,
According to Spherix Global Insights first market landscape study on Amyotrophic Lateral Sclerosis (ALS), general neurologists lack awareness of therapies
According to Spherix Global Insights, U.S. neurologists are largely satisfied with current treatment choices in the RMS market, but opportunities remain.
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global
According to Spherix Global Insights, US Rheumatologists are taking increasing ownership over lupus nephritis (LN) patient management, yet they are
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals
